Reuters logo
BRIEF-Revance announces positive top-line 24-week duration of effect results in all three cohorts in RT002 injectable phase 2 cervical dystonia trial
2017年5月18日 / 晚上8点22分 / 6 个月前

BRIEF-Revance announces positive top-line 24-week duration of effect results in all three cohorts in RT002 injectable phase 2 cervical dystonia trial

May 18 (Reuters) - Revance Therapeutics Inc

* Revance announces positive top-line 24-week duration of effect results in all three cohorts in RT002 injectable phase 2 cervical dystonia trial

* Company also announced additional positive efficacy results and that RT002 was generally safe and well-tolerated

* In all three cohorts, RT002 injectable appeared to be generally safe and well-tolerated through week 24

* Revance Therapeutics- Based on phase 2 results, expects to discuss next steps in clinical program with US and EU regulatory agencies later this year Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below